Oncimmune Holdings significant Q2 FY2022 sales and expansion of business development team in US and Europe

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, today provided an update on commercial activity within its ImmunoINSIGHTS pharma services business.

As we highlighted in the full year results announcement released on 2 November 2021, the ImmunoINSIGHTS pharma services business has been benefiting from a ramp-up in commercial activity moving into Q2 FY2022. During this second quarter ended 30 November 2021, a number of contracts were signed for both new customers as well as for customers for whom we have already completed studies. As a result of this activity, the ImmunoINSIGHTS business has posted its biggest quarter by contract wins since the business was launched in February 2020.

Whilst respecting commercial confidentiality, summary details of a number of these ImmunoINSIGHTS contracts is provided as follows:

·      a collaboration contract with a new large pharma partner headquartered in Germany, to characterise the Immunoglobulin G (IgG) autoantibody profiles of patients in clinical trials for Systemic Lupus Erythematosus (SLE)[1]. The study will explore baseline autoantibody profiles as biomarkers of disease, adverse events and clinical response in patients. ImmunoINSIGHTS will use its proprietary NavigAID SLE panel to characterise autoantibody profiles from trial participants in a pilot project; and

·      a contract with another new large pharma partner to characterise the autoantibody profiles of patients in clinical trials for SLE1. In this new project, ImmunoINSIGHTS will use its proprietary SeroTag panel to characterise autoantibody profiles from trial participants. Following completion of this project, there will be further contracting opportunities for additional samples. One objective of this project includes better characterisation of the disease, where there is a high unmet need for an effective therapy

These and other large pharma contracts add to the stable of biotech contracts signed earlier in FY2021, under which work is currently being progressed in the ImmunoINSIGHTS facility in Dortmund, Germany. In addition to these recent contract wins, there are a number of further contracts which are expected to be signed this month, including a further contract with another existing large pharma partner. A further commercial update is expected to be issued before Christmas with details of these further contract wins. The servicing of these contracts has been made possible following further investment in equipment and personnel to scale up the Dortmund facility.

At the time of the equity fundraising in March 2021 to support this growth, the Company also identified the need to expand its sales and business presence in the US to meet the growing demand for commercial engagement from US-based pharmaceutical and biotech companies. The Company is therefore pleased to announce the appointment of Cameron Barnard to the position of Chief Business Officer. Cameron joined the Company in late August and is based in Boston, USA. Cameron has already made an immediate impact on contract wins as well as building the US-based commercial team using some of the proceeds from the equity raise.

Following a recent market analysis performed by an independent strategy consultancy, we are able to size the potential demand for the ImmunoINSIGHTS pharma services with greater accuracy. In order to capitalise on this demand, it is anticipated that the commercial team will be expanded to comprise multiple sales executives based in the US and a growing team of sales executives based in Europe. The appropriate sizing of these teams will be determined before the end of the current financial year. This significantly enlarged commercial team is expected to generate significant pipeline opportunities and sales momentum during FY2022 and beyond.

Cameron Barnard, Chief Business Officer of Oncimmune, said“I am excited to have joined Oncimmune and lead a team that is quickly becoming the partner of choice and global leader in immunodiagnostics. Our ImmunoINSIGHTS platform has vast commercial potential with its robust technology, proven utility in support of critical clinical therapeutic development, and a highly experienced scientific team. The potential for ImmunoINSIGHTS has been validated by my network of commercial professionals and pharma and biotech contacts. I am in the process of building a world-class demand generation and conversion team to further capture the impressive commercial opportunity available to the Company.”

Dr Adam M Hill, CEO of Oncimmune, said: “The commercial momentum we have experienced in Q2 FY2022 has not only resulted in contract wins but is expected to lead to further signed contracts in the coming weeks and, importantly, throughout Q3 FY2022 and beyond. Our key customers continue to provide follow-on contracts and our expanding commercial team is not only growing our commercial pipeline but also delivering a broadening and deepening of our customer relationships.”

Click to view all articles for the EPIC: ,
Or click to view the full company profile:
    Share on facebook
    Share on twitter
    Share on linkedin

    More articles like this

    Fintel plc

    Fintel core revenue growth is higher than Zeus forecast

    Fintel plc (LON:FNTL), the leading provider of Fintech and support services to the UK retail financial services sector, has released a trading update for the six months to 30 June 2022, which reveals: Core revenue grew c.9% to

    Shoe Zone plc

    Shoe Zone analyst Zeus upgrades FY22 adjusted PBT forecast

    Shoe Zone plc (LON:SHOE) Better than expected demand and further strong margin performance leads to an upgrade in FY22E adjusted PBT from “no less than £8.5m” to “no less than £9.5m”. Zeus revenue forecasts increase by £1.5m (1.0%)

    OnTheMarket Plc

    OnTheMarket analyst Zeus confident in forecasts

    Foxtons, one of London’s leading estate agencies with more than 50 interconnected branches across London, has signed an agreement to advertise its UK residential sales and letting properties at OnTheMarket plc (LON:OTMP). Zeus view: Foxtons, the well-known London

    SpaceandPeople analyst Zeus restores estimates and valuation

    SpaceandPeople plc (LON:SAL) secures, sells, and manages flexible space for brand experiences, short term promotions and retailing in high footfall venues for its customers, including in shopping centres and travel hubs. The Group has issued a positive pre-close

    Lookers Plc

    Lookers shares are still undervalued says Zeus

    Lookers plc (LON:LOOK) has released an H1 trading update reporting a continuation of strong performance year to date. H1 2022 underlying PBT is expected to be c. £45m and Management anticipate full year PBT will also be ahead

    SysGroup plc

    SysGroup analyst Zeus forecast a 39.0% increase in revenue in FY23

    SysGroup plc (LON:SYS) is an award-winning provider of managed IT services, cyber security, cloud hosting and IT consultancy. The Group offers investors an attractive business model with high recurring revenue and a diversified customer base. SysGroup is competitively

    AFC Energy

    AFC Energy’s long term opportunity remains vast says Zeus

    AFC Energy plc (LON:AFC) has signed an agreement with another leading UK construction/infrastructure player, this time in Kier Group. We believe this further endorses our long term thesis that AFC will play an active role in encouraging the


    Inchcape performance exceeding expectations says Zeus

    Inchcape plc (LON:INCH) has released another positive trading update, with performance exceeding expectations so far this year. This follows on from a positive Q1 update on 28 April. Through quarterly improvement in Distribution volumes and operating margin, the

    boohoo Plc

    Boohoo Group analyst Zeus sees a strong performance in Q1

    ¨ Q1 financial highlights: Boohoo Group plc (LON:BOO) revenue of £445.7m is -8.3% YOY vs. a strong comp (Q1 FY22 revenue +32.1%), in line with Zeus’s forecast and management’s previously stated guidance. Gross sales growth remained positive +9%

    No more posts to show